Evaluation of withdrawal of maintenance tiotropium in COPD

Respiratory Medicine

Volumn 103, Issue 10, 2009, Pages 1415-1420

  Adams, Sandra G ^a   Anzueto, Antonio ^a   Briggs Jr , Dick D ^b   Leimer, Inge ^c   Kesten, Steven ^c  

^a UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^b UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^c BOEHRINGER INGELHEIM PHARMA GMBH AND CO KG   (Germany)

Author keywords

COPD; Peak expiratory flow rate; Spirometry; St. George's Respiratory Questionnaire; Tiotropium; Transition dyspnea index

Indexed keywords

BETA ADRENERGIC RECEPTOR STIMULATING AGENT; IPRATROPIUM BROMIDE; PLACEBO; TIOTROPIUM BROMIDE; XANTHINE;

ADULT; AGED; ARTICLE; CHRONIC OBSTRUCTIVE LUNG DISEASE; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; DYSPNEA; FEMALE; FOLLOW UP; FORCED EXPIRATORY VOLUME; HUMAN; MAJOR CLINICAL STUDY; MALE; PEAK EXPIRATORY FLOW; PRIORITY JOURNAL; SMOKING; TREATMENT RESPONSE; TREATMENT WITHDRAWAL;

AGED; BRONCHODILATOR AGENTS; DYSPNEA; EPIDEMIOLOGIC METHODS; FEMALE; FORCED EXPIRATORY VOLUME; HUMANS; MALE; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; QUALITY OF LIFE; SCOPOLAMINE DERIVATIVES; WITHHOLDING TREATMENT;

EID: 69249215521     PISSN: 09546111     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.rmed.2009.05.018     Document Type: Article

References (18)

1. Rabe K., Hurd S., Anzueto A., et al. Global initiative for chronic obstructive lung disease. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. GOLD executive summary. Am J Respir Crit Care Med 176 (2007) 532-555
2. Celli B.R., and MacNee W. Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paper. Eur Respir J 23 (2004) 932-946
3. Mahler D.A., Weinberg D.H., Wells C.K., et al. The measurement of dyspnea. Contents, interobserver agreement, and physiologic correlates of two new clinical indexes. Chest 85 (1984) 751-758
4. Jones P., Quirk F., Baveystock C., et al. A self-complete measure of health status for chronic airflow limitation. The St. George's Respiratory Questionnaire. Am Rev Respir Dis 145 (1992) 1321-1327
5. Disse B., Speck G.A., Rominger K.L., Witek T.J., and Hammer R. Tiotropium (Spiriva): mechanistic considerations and clinical profile in obstructive lung disease. Life Sci 64 (1999) 457-464
6. Casaburi R., Mahler D.A., Jones P.W., et al. A long-term evaluation of once-daily inhaled tiotropium in chronic obstructive pulmonary disease. Eur Respir J 19 (2002) 217-224
7. American Thoracic Society. Standards for the diagnosis and care of patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 152 (1995) S77-S121
8. Vincken W., van Noord J.A., Greefhorst A.P.M., Bantje Th.A., Kesten S., Korducki L., et al. Improved health outcomes in patients with COPD during 1 year's treatment with tiotropium. Eur Respir J 19 (2002) 209-216
9. Brusasco V., Hodder R., Miravitlles M., Korducki L., Towse L., and Kesten S. Health outcomes following treatment for six months with once daily tiotropium compared with twice daily salmeterol in patients with COPD. Thorax 58 (2003) 399-404
10. O'Donnell D.E., Fluge T., Gerken F., et al. Effects of tiotropium on lung hyperinflation, dyspnea and exercise tolerance. Eur Respir J 23 (2004) 832-840
11. Maltais F., et al. Improvements in symptom-limited exercise performance over 8 h with once-daily tiotropium in patients with COPD. Chest 128 (2005) 168-178
12. Niewoehner D.E., Rice K., Cote C., Paulson D., Cooper Jr. J.A.D., Korducki L., et al. Prevention of exacerbations of chronic obstructive pulmonary disease with tiotropium, a once-daily inhaled anticholinergics bronchodilator. Ann Intern Med 143 (2005) 319-326
13. Dusser D., Bravo L., Iacono P., and on behalf of the MISTRAL study group. The effect of tiotropium on exacerbations and airflow in patients with COPD. Eur Respir J 27 (2006) 547-555
14. Jarad N.A., Wedzicha J.A., Burge P.S., and Calverley P.M. An observational study of inhaled corticosteroids withdrawal in stable chronic obstructive pulmonary disease. ISOLDE Study Group. Respir Med 93 (1999) 161-166
15. O'Brien A., Russo-Magno P., Karki A., et al. Effects of withdrawal of inhaled steroids in men with severe irreversible airflow obstruction. Am J Respir Crit Care Med 164 (2001) 365-371
16. van der Valk P., Monninkhof E., van der Palen J., Zielhuis G., and van Herwaarden C. Effect of discontinuation of inhaled corticosteroids in patients with chronic obstructive pulmonary disease. The COPE study. Am J Respir Crit Care Med 166 (2002) 1358-1363
17. Wouters E.F.M., Postma D.S., et al., for the COSMIC (COPD and Seretide: a Multi-Center Intervention and Characterization) study Group. Withdrawal of fluticasone propionate from combined salmeterol/fluticasone treatment in patients with COPD causes immediate and sustained disease deterioration: a randomized controlled trial. Thorax 60 (2005) 480-487
18. Suissa S., Ernst P., Vandemheen K.L., and Aaron S.D. Methodological issues in therapeutic trials of chronic obstructive pulmonary disease. Eur Respir J 31 (2008) 927-933